NL-OMON47648已完成不适用
Integrated pharmacokinetics of infliximab, adalimumab and golimumab in serum, tissue and faeces of patients with moderate to severe Ulcerative Colitis and Crohn's Colitis - Three compartment PK study
Maag-, darm-, leverziekten0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients aged * 18 years, either male or female, moderate to severe Ulcerative
- •Colitis or Crohns* colitis (respectively according to Mayo score (2 or 3) or
- •SES-CD (*7) at baseline endoscopy), starting on Infliximab, adalimumab or
- •golimumab at regular doses.
排除标准
- •Contra-indications to anti-TNF treatment, imminent need for surgery.
研究者
相似试验
进行中（未招募）
不适用
The degradation and elimination of InfliximabInflammatory bowel disease (Ulcerative Colitis, Crohn's disease)MedDRA version: 17.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 17.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-001332-29-ATniversitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie
已完成
不适用
Study of the pharmacokinetics of Infliximab (IFX) in moderate to severe Ulcerative ColitisInflammatory Bowel Disease10017969Ulcerative ColitisNL-OMON37516Academisch Medisch Centrum20
尚未招募
4 期
Pro-RAPIDCrohn's Disease2023-507352-72-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)50
尚未招募
4 期
Prospective Analysis of Pharmacokinetic Infliximab data in Paediatric Inflammatory Bowel Disease patientsCrohn's diseaseNL-OMON51805Erasmus MC, Universitair Medisch Centrum Rotterdam49
进行中（未招募）
1 期
Prospective Analysis of Pharmacokinetic Infliximab data in Paediatric Inflammatory Bowel Disease patients (Pro-RAPID)Crohn's DiseaseCTIS2023-507352-72-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)50